JMP Securities analyst Eric Ross reiterates Vacasa (NASDAQ:VCSA) with a Market Outperform and maintains $3 price target.
Armata Pharmaceuticals Announces Completion Of Its Phase 1b/2a ‘SWARM-P.a.’ Study Of Inhaled AP-PA02 In Cystic Fibrosis Subjects With Chronic Pulmonary Pseudomonas aeruginosa Infection
Armata Pharmaceuticals, Inc. (NYSE:ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat
